ABOUT US

history

Every Journey Starts With a Step

We started ours in 1989 when our founders, Randy W. Hamilton and Lorin K. Johnson, PhD, realized the need for more effective gastrointestinal solutions. Since then, Salix hasn’t stopped moving forward.

1989

- Salix Pharmaceuticals is founded in Sunnyvale, California

1990

- COLAZAL® (balsalazide disodium) is licensed

1996

- XIFAXAN® (rifaximin) is licensed

2000

- Operations move to Raleigh, North Carolina
- COLAZAL® (balsalazide disodium) receives FDA approval

2004

- XIFAXAN® (rifaximin) 200 mg receives FDA approval for treatment of non-invasive traveler's diarrhea

2006

- MOVIPREP® (PEG-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid for oral solution) receives FDA approval

2008

- APRISO® (mesalamine granules) receives FDA approval
- RELISTOR® (methylnaltrexone bromide) subcutaneous injection receives FDA approval for opioid-induced constipation (OIC) in adults with advanced illness when other medicines for constipation have not worked well enough

2009

- OSMOPREP® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP) receives FDA approval

2010

- XIFAXAN® (rifaximin) 550 mg receives FDA approval for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults

2013

- UCERIS® (budesonide) extended-release tablets receives FDA approval
- GIAZO® (mesalamine) receives FDA approval

2014

- Salix acquires Santarus
- RELISTOR® (methylnaltrexone bromide) subcutaneous injection receives FDA approval for OIC in adults with chronic non-cancer pain

2015

- UCERIS® (budesonide) rectal foam receives FDA approval
- XIFAXAN® (rifaximin) 550 mg receives FDA approval for irritable bowel syndrome with diarrhea (IBS-D) in adults
- Valeant acquires Salix
- Operations begin moving to Bridgewater, New Jersey, our current location

2016

- Salix launches RELISTOR® (methylnaltrexone bromide) tablets

2017

- Salix scales up sales force by nearly 40 percent

2018

- Valeant changes name to Bausch Health
- Salix launches PLENVU® (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride for oral solution)
- Salix launches LUCEMYRA (lofexidine) tablets 1.18mg

2019

- Salix celebrates three decades of GI solutions
- Bausch Health completes acquisition of certain assets of Synergy Pharmaceuticals, including Trulance (plecanatide)